Xenetix

Selected form

Iobitridol

Method of action: Contrast Media, Radiopaque

Treatment option: Angiography, Angiocardiography, Intravenous Urography, Computed Tomography Scan, Urography

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Xenetix

Property	Description
Active Ingredient	Iobitridol
Form	Sterile aqueous solution for injection
Pharmacological Class	Radiopaque medium / Iodinated contrast agent
General Purpose	Enhancing contrast for diagnostic imaging
Origin	Synthetic tri-iodinated benzene derivative

Xenetix is a specialized, prescription-only diagnostic agent used exclusively to enhance the visibility of internal body structures during X-ray-based medical procedures. Its role is not therapeutic—it does not treat disease—but rather to provide the clarity necessary for an accurate diagnosis. The drug belongs to the radiocontrast medium class, categorized under the Anatomical Therapeutic Chemical (ATC) classification system as V08AB11. Iobitridol belongs to the low-osmolality, non-ionic contrast media group, a classification characterized by its favorable properties during intravascular administration.

What Type of Agent is Xenetix (Iobitridol)?

Xenetix is defined by its active ingredient, Iobitridol, which is a synthetic tri-iodinated benzene derivative. This ingredient is recognized for its high iodine content, which is the chemical feature responsible for the solution's radiopaque property. The medication is formulated as a sterile aqueous solution for injection intended for intravascular administration (into a vein or artery). Iobitridol is a single-ingredient product characterized by its non-ionic, low osmolality properties, differentiating it from older, higher osmolality contrast agents. This formulation is typically utilized in procedures targeting the visualization of circulatory or urinary systems.

General Purpose: What Does Xenetix Help Achieve?

The primary purpose of Xenetix is to achieve maximum image contrast enhancement in diagnostic radiology procedures, such as angiography (visualizing blood vessels) and computed tomography (CT). When injected, the iodine atoms within the Iobitridol molecule effectively absorb X-rays, a process known as X-ray attenuation. This action makes the blood vessels and soft tissues containing the agent appear bright white on the image, distinguishing them clearly from surrounding structures. By temporarily improving the visual delineation of internal anatomy, Xenetix allows clinicians to perform detailed assessments crucial for making informed diagnostic decisions.

Regulatory References

What side effects are possible with Xenetix?

Possible side effects and safety information

The safety profile for Xenetix (Iobitridol) is formally categorized according to regulatory standards, classifying potential adverse reactions by both frequency and the physiological systems affected.

Frequency-Classified Adverse Reactions

Adverse effects are documented in official regulatory sources using standardized frequency bands:

Common (1/100 to <1/10): Nausea, Headache, Urticaria (hives).
Uncommon (1/1,000 to <1/100): Vomiting, Dizziness, Hypotension (low blood pressure), and injection site reactions (e.g., pain or warmth).
Rare (1/10,000 to <1/1,000): Serious events including Seizure, Cardiac arrest, Anaphylactic shock, and Acute renal failure.

These reactions are grouped into System-Organ Classes (SOC), spanning areas such as Immune system disorders, Nervous system disorders, Cardiac disorders, Vascular disorders, and Renal and urinary disorders.

Serious Adverse Reactions and Special Safety Considerations

The most serious reactions, which are classified as rare, include Anaphylactic Shock, Cardiac Arrest, and Acute Renal Failure. The temporal relationship of adverse events is officially noted, with most severe immediate reactions occurring within 60 minutes, though delayed reactions (e.g., rash, fever) may appear up to seven days later.

Population-Specific Notes identify increased risks for certain patients, specifically noting that individuals with pre-existing renal impairment (especially those with diabetes or multiple myeloma) are at heightened risk for Acute Kidney Injury. Official safety constraints also mandate caution for patients with manifest thyrotoxicosis or those taking metformin, due to the documented safety consequence of potential lactic acidosis following contrast-induced renal dysfunction.

This structure ensures that the full spectrum of officially acknowledged risks is communicated in a neutral, medically grounded manner.

Overdose and Emergency Response

Overdose and When to Seek Help

Since Xenetix (iobitridol) is administered exclusively by trained medical professionals within a monitored clinical setting, any suspected overdose is immediately managed by the administering healthcare team. The official regulatory profile for this radiocontrast agent is focused on procedural management and supportive actions, rather than listing specific symptoms arising from pure over-administration.

Regulator-Mandated Management

Immediate medical intervention is required for supportive care in the event of a clinically significant overdose. No specific antidote is known for Iobitridol. Therefore, official management is limited to symptomatic and supportive treatment.

The primary method documented in regulatory information for reducing the systemic concentration of the active substance is clearance via haemodialysis. This procedure is explicitly recognized as a means of systemic removal.

Following an overdose, continuous medical observation is necessary. This monitoring includes a required check of renal function for a period of at least three days. Furthermore, regulatory documents advise that careful correction of water and electrolyte balance is particularly important in the management of small children and elderly patients who may experience an over-administration.

Therapeutic Uses of Xenetix

What Xenetix Treats: Main Uses and Benefits

Quick Facts

Primary Use: Supports diagnostic visualization during radiological examinations.
Key Areas of Study: Helps delineate internal structures in angiography and computed tomography (CT).
Specific Modalities: Used in intravenous urography and angiocardiography procedures.

Xenetix (iobitridol) is a pharmaceutical product designated for diagnostic use only. It serves to enhance the contrast of images obtained during certain types of X-ray and computed tomography (CT) examinations. This supports diagnostic efforts by improving the delineation and visualization of specific internal structures within the body.

This agent is administered to assist in procedures such as intravenous urography, which focuses on the urinary system, and angiocardiography, which allows for the study of the heart and its major blood vessels. It is also an available option for arteriography and imaging of the whole body via CT scanning. The use of this contrast agent is intended to provide healthcare professionals with clearer images, which may support the process of medical assessment of patient anatomy and function. This product is suitable for administration to both adult and pediatric patient populations within its approved indications.

Eligibility and Restrictions for Use

Official Eligibility for Xenetix (Iobitridol)

Regulatory authorities define strict rules governing who can and cannot receive Xenetix, an iodinated contrast agent. Eligibility is determined by absolute contraindications, patient age, organ function, and specific comorbidities.

Absolute Contraindications

The following groups must not use Xenetix:

Patients with known hypersensitivity to iobitridol or its excipients.
Patients with manifest thyrotoxicosis (overactive thyroid).
Patients with a history of a major immediate or delayed cutaneous reaction to any previous iodinated contrast agent.
Pregnant women requiring the procedure hysterosalpingography.

Conditional and Restricted Use

Use is restricted in several populations due to increased risk or the need for special management:

Organ Impairment: Patients with renal insufficiency or hepatic insufficiency require caution. Use in combined severe hepatic and renal impairment is strongly discouraged.
Age Groups: The medication is generally suitable for adults and children, but infants under one year and elderly subjects are considered at-risk populations and require close monitoring.
Comorbidities: Patients with severe cardiovascular disease, pheochromocytoma, or those with Monoclonal Gammopathy necessitate special precautions. Diabetic patients taking Metformin must suspend the drug temporarily following injection.
Pregnancy/Lactation: Use is not recommended during pregnancy after 14 weeks of amenorrhoea. It is advisable to stop breastfeeding for 24 hours after administration.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Xenetix (iobitridol) details specific, documented interactions with other medicines and substances. The primary focus of these restrictions is the management of risk related to severe reactions and renal safety, as described in authoritative government documents.

Interacting Substance	Official Regulatory Statement
Metformin	Use is contraindicated in patients with abnormal kidney function. If kidney function is normal, treatment must be suspended 48 hours before the examination and only reinstituted two days afterward.
Beta-blockers	Co-administration may increase the risk of moderate to severe anaphylactoid reaction and potentially reduce the effectiveness of necessary emergency treatments.
Diuretics	When used in a way that causes dehydration, these agents officially increase the risk of acute kidney failure, particularly with high doses of the contrast medium.

Mechanism of Action

Xenetix (iobitridol) functions via a physical mechanism centered on the high atomic number of its three iodine atoms (Z=53), which are the core biological targets of the X-ray beam. The primary interaction is X-ray photon absorption, leading to radiopacity. After administration, this hydrophilic molecule is passively distributed throughout the extracellular fluid space, including the bloodstream, but does not readily cross cell membranes or the blood-brain barrier. This biophysical cascade results in the agent being highly concentrated within the vascular and interstitial compartments, causing the creation of temporary contrast against surrounding tissues. Xenetix is not metabolized; its elimination cascade involves rapid, unchanged clearance by the renal system through glomerular filtration. This process results in the radiopaque concentration of the tubular fluid within the renal collecting system before the contrast effect dissipates, providing system-level physiological consequence.

Dosage and Administration Information

Xenetix (iobitridol) is a non-ionic, iodinated contrast agent administered for diagnostic purposes in various radiological examinations, including Computed Tomography (CT) scans, angiography, and intravenous urography. It is provided as a sterile solution for injection in concentrations such as 250, 300, and 350 mg of iodine per mL.

Administration and Dosage

Administration of Xenetix is performed by a qualified healthcare professional, typically via intravascular injection, which can be either intravenous or intra-arterial, or through other local routes for specific examinations (e.g., intra-articular or intra-uterine). The drug is usually given as a single dose.

Dose determination is individualized, based on the specific type of examination being performed, the patient's body weight, and their renal function. The goal is always to use the lowest effective dose necessary to achieve adequate diagnostic contrast. The rate of injection can vary significantly, often between 0.5 and 5 mL/s, depending on the procedure and equipment used.

Essential Precautions

Prior to administration, patients should inform their physician about any history of allergic reactions to iodinated contrast media, pre-existing conditions like renal or hepatic impairment, diabetes mellitus, or thyroid disorders.

Hydration: Maintaining adequate hydration both before and after the procedure is important, particularly for patients with compromised renal function or diabetes, to minimize the risk of kidney deterioration.
Monitoring: The injection and subsequent patient observation must be performed under medical supervision. Patients are typically monitored for at least 30 minutes after administration, as most serious adverse reactions occur within this timeframe. Patients should be aware that delayed reactions can occur up to several days later.

Common Routes of Administration	Examples of Examinations
Intravascular (IV or IA)	CT scan, Angiography, Urography
Local	Arthrography (joints), Hysterosalpingography (uterus/fallopian tubes)

Recent Clinical Evidence

Research Evidence: Overview of Studies for Xenetix (Iobitridol)

The research available for Xenetix reflects its design as an agent intended to temporarily enhance contrast in images taken during specific medical procedures. Studies explore its utility, rather than focusing on the treatment of disease. Evidence is primarily derived from controlled trials that compare iobitridol to other contrast agents and from very large, non-interventional studies that monitor its use in clinical settings.

Evidence for Use in Computed Tomography (CT) Scanning

Clinical research, including short-term, multicenter Randomized Controlled Trials (RCTs), was evaluated in patients undergoing various types of CT scans. Researchers examined outcomes such as the overall diagnostic image quality and the quality of specific structures, like the coronary arteries, needed to assess narrowing. Observational studies reported patterns where a high rate of diagnostically informative examinations was observed in very large, real-world studies.

Comparative trials also examined the proportion of scans rated as fully evaluable for diagnosis when comparing iobitridol to other contrast agents. Long-term effects are not fully established regarding the diagnostic quality of images taken long after administration, as most research focuses on the immediate procedure time.

Evidence for Use in Angiography and Angiocardiography

Studies exploring iobitridol’s use in imaging blood vessels and the heart primarily consisted of comparative randomized trials. The research examined key outcomes such as global image quality and the quality of specific blood vessel opacification (visibility), which is necessary for diagnostic assessment.

Comparative trials studied for the global image quality, reporting that the proportions of examinations with clear images were similar between iobitridol and the other tested non-ionic contrast agents. Evidence was observed in studies exploring the use of the agent in pediatric populations, contributing to the evidence base for this population. Sample sizes were modest in some focused comparative trials.

Research in Special Patient Populations

Research has explored the use of iobitridol in patient populations that extend beyond general adults, including pediatric patients and adults with common co-existing conditions such as diabetes or hypertension. Findings describe patterns observed in the studies where high rates of diagnostic success were seen even in these diverse, complex patient cohorts. Data for certain groups remain insufficient for specific, randomized head-to-head comparisons.

Key Studies & References

How should Xenetix be stored and disposed of?

How to Store and Dispose of Xenetix

The storage and disposal of Xenetix (iobitridol) must adhere strictly to the conditions specified in the official regulatory labeling.

Storage Requirements

Xenetix must be stored at a temperature that does not exceed 30 C. The container should be kept in the original outer carton to ensure protection from light. Do not use the product after the stated expiry date. Once a single-dose container is opened, the solution must be used immediately to maintain sterility, and any unused portion must be discarded.

Handling and Disposal

For administration, the solution is typically warmed to body temperature (37 C). It is mandatory to keep this medicine out of the sight and reach of children. Disposal of unused product and waste materials must follow local requirements and hospital procedures. Medicines should not be discarded via wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.